Forian Inc (FORA)vsNovartis AG ADR (NVS)
FORA
Forian Inc
$2.17
0.00%
HEALTHCARE · Cap: $67.79M
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 188168% more annual revenue ($56.58B vs $30.05M). NVS leads profitability with a 23.9% profit margin vs -17.0%. FORA appears more attractively valued with a PEG of 0.94. NVS earns a higher WallStSmart Score of 49/100 (D+).
FORA
Avoid29
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FORA.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -17.9% — below average capital efficiency
Revenue declined 2.9%
Earnings declined 89.1%
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : FORA
The strongest argument for FORA centers on PEG Ratio, Price/Book. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : FORA
The primary concerns for FORA are Market Cap, Return on Equity, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
FORA profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
FORA carries more volatility with a beta of 0.93 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Forian Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Forian Inc. provides a suite of software solutions, data management capabilities, proprietary data, and predictive analytics to optimize and measure operational, clinical, and financial performance for clients in the health and cannabis industries, as well as dispensaries. , cannabis growers, manufacturers, and distributors. The company is headquartered in Newtown, Pennsylvania.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?